• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Healthcare·SUN.L
Share

Surgical Innovations Group plc Stocks

£ 0.5Last Updated 09.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

£ 6.22M

£ 0.5
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precision engineering applications. Its global presence extends across the UK, Europe, the Asia Pacific region, and the United States. The company operates through three distinct divisions: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment is responsible for the research, development, production, and commercialization of its proprietary SI-branded minimally invasive instruments. Key products within this portfolio include the YelloPort Elite and YelloPort +plus laparoscopic port access systems, LogiRange resposable laparoscopic instrument systems, FastClamp laparoscopic clamping systems, and QuickRange single-use laparoscopic instrumentation. The OEM division focuses on crafting and supplying minimally invasive devices for third-party medical device firms, often under their own brand or through co-branding arrangements. This segment also provides comprehensive design and development solutions for creating final medical devices and is involved in the research, development, manufacturing, and sale of minimally invasive technology tailored for precision engineering. Lastly, the Distribution segment handles the supply of various medical products, primarily via its subsidiary, Elemental Healthcare Ltd, and also designs and produces autologous blood products. Surgical Innovations Group plc sells its offerings through a network of independent healthcare distributors, while its own-label products are also distributed through its OEM collaborations.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is 'expensive' on EV/EBITDA, trading at neutral levels on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.07.2026 01:30

User-generated content is Reddit's advantage in the age of AI, according to an analyst

11.07.2026 01:21

SK Hynix's First Day of Trading in the U.S. and Meta's Surge: The Market Bet on AI on Friday

11.07.2026 00:31

Meta Shares Are on Track for Their Best Weekly Performance in 2.5 Years Thanks to New AI

10.07.2026 23:06

Delta's profits were eaten up by record fuel costs. But revenue was buoyed by demand

10.07.2026 21:56

An Unwelcome Measure: Why Kazakhstan Is Abolishing the Mandatory Sale of Foreign Currency Proceeds

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026